-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on BridgeBio Oncology, Maintains $25 Price Target

Benzinga·09/09/2026 12:21:06
語音播報
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform and maintains $25 price target.